Medical network - on April 5, according to flush the data as of April 1, A shares issued A total of 114 listed companies in 2016 annual report, including 84 listed companies performance year-on-year growth, accounted for about 74%. Another, according to the securities journal reporter this 114 listed biological medicine (love base, net, information) in the enterprise, 97 listed companies cash dividends, proposed 85%. 

 

High drug sales gross profit margin has been one of the focus of capital market. Flush, according to data from 25 sales gross profit margin of listed companies by more than 70%. 

 

More than eighty percent company intends to cash dividends 

 

Data show that last year net profit growth of 31 listed companies spend one hundred million yuan. New and into them (002001) in 2016 net profit attributable to shareholders of listed companies in 2015 than the value increase of about 800 million yuan, for the first. 

 

Out the survey, chemical pharmaceutical field 41 issued 2016 transcripts of listed companies, including 32 listed companies performance year-on-year growth; Biological products field 16 listed company issued 2016 transcripts, 14 listed company performance for growth; 31 listed companies in Chinese medicine, 18 listed companies earnings growth; Pharmaceutical business section 12 just huatong medicine (002758) of the listed company performance decline; Medical instrument plate 9 listed company YangPu medical (300030), three xin medical biological (300298) (300453), and three performance decline; Medical services sector five listed companies, jinling pharmaceutical, medical (600763) performance decline. 

 

When regulators advocate listed companies pay dividends, medicine, biological dividends of listed companies is positive. 

 

As of April 1, the medical listed companies have 97 listed companies cash dividends proposed, including 37 cash dividends of listed companies a total of one hundred million yuan. Harbin pharmaceutical corporation (600664), step length pharmaceutical (603858) in cash dividends amount exceeds one billion yuan. 

 

Harbin pharmaceutical shares in 2016 annual report, according to the company profit situation and need to return for shareholders and deliberated by the board of directors of the company, the company 2016 annual profit distribution plan is: in a total of about 2.54 billion shares of base, every 10 shares distributed to all the shareholders according to the 5 yuan (including tax), cash dividend distribution of cash dividend of about 1.27 billion yuan. 

 

Step pharmaceutical 2016 annual report, passed by the board of directors of the company 2016 annual profit distribution plan is: through December 31, 2016, the company's total share capital of 681.8 million shares for the base, using undistributed profit every 10 shares allocated to all the shareholders in cash dividend of 16.14 yuan (including tax), a total of distributing cash dividend of about 1.1 billion yuan (including tax). 

 

25 companies sales gross profit margin by more than 70% 

 

Flush, according to the cable car glides (300204), the wisdom god flying creatures (300122), hengrui pharmaceutical (600276), and wide hall (300436), sichuan pharmaceutical industry (600566), step length KaiBao pharmaceutical, Shanghai (300039) sales gross profit margin by more than 80%. Out the survey, the cable car glides, intellectual flying creatures god, wide raw don belong to biological products industry, hengrui medicine, sichuan pharmaceutical pharmaceutical industry belongs to the chemical field, step length pharmaceutical industry, Shanghai KaiBao belongs to traditional Chinese medicine (TCM). 

 

Since 2012, according to the cable car glides god, for six consecutive years sales gross profit margin by more than 90%. Cable car glides god, according to the annual report in 2016 during the reporting period, the company to meet the annual business income is 1.403 billion yuan, the operating profit of 295 million yuan, belong to shareholders of listed companies net profit of 257 million yuan. Company main product is innovative drug Sue peptides (injectable mouse nerve growth factor) and the national exclusive sf-peg. Last year, Sue peptide raw sales gross profit margin of 97.12%. 

 

Hengrui pharmaceutical 2016 operating income of 2016 yuan, up 19.08% from 2015. Realize net profit attributable to shareholders of listed companies of 2.589 billion yuan, up 19.22% from a year earlier. Last year, tablet, injection drug sales gross profit margin of 89.4%, 87.29% respectively. 

 

Step length pharmaceutical 2016 annual report showed that last year, the company operating income of 12.321 billion yuan, up 5.71% from a year earlier. Gross margin was 83.17%, year-on-year increase of 0.38%. 

 

It is worth mentioning that in medical policy adjustment in 2016, some listed companies' profit margins fell. 

 

Assist force pharmaceutical (300181) 2016 annual report, company pharmaceutical manufacturing sector gross margin was 71.4%, the value is 81.44% in 2015, fell nearly 10%. In addition, xiangxue pharmacy (300147), Kang Zhi pharmaceutical (300086), jincheng pharmaceutical (300233) and other product sales gross profit margin of listed companies have different degrees of decline.